Glaucocalyxin B Relieving Dyskinesia Inflammation and Oxidative Stress in Parkinson's Disease Model Rats by Activating the NRF2/HO-1 Pathway

To analyze that glaucocalyxin B can alleviate dyskinesia, inflammatory response and oxidative stress in Parkinson's disease model rats by activating the nuclear factor erythroid 2–related 2/heme oxygenase-1 pathway. 150 adults were divided into 5 groups, namely, sham operation group (healthy mice), low-dose (Parkinson+20 ng/ml) B), medium-dose (Parkinson+40 ng/ml B) high-dose (Parkinson+60 B). The number of adjustment steps, forepaw movements positive reactions each at 0 d have no difference; on 3rd group, dose reduced than group; 7th d, steps groups group. tumor necrosis factor-alpha, interleukin-1 beta interleukin-6 raised those while these reactive concentration myeloperoxidase activity superoxide dismutase level was levels 2-related heme Further, low, medium high increased with increase (p<0.05). Glaucocalyxin dyskinesia reduce rats, its relevant mechanism via